APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Parkinson Disease Drug

Most people with Parkinson's disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Most people with Parkinson's disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement.

Selected research

Industry Growth & Trends

Global Parkinson Disease Drug Industry Growth and Trends Forecast to 2032

Report ID 174022410121 December 2025110 pages

Choose your research edition.

Industry ResearchParkinson Disease Drug Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Parkinson Disease Drug Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Parkinson Disease Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Parkinson Disease Drug Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Parkinson Disease Drug Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

Most people with Parkinson's disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement.

According to APO Research, the global Parkinson Disease Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

Report Scope

Read the full market overview

This report provides a structured, data-driven view of the global Parkinson Disease Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Parkinson Disease Drug market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Parkinson Disease Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Parkinson Disease Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Parkinson Disease Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Parkinson Disease Drug Market by Company

Merck

Akorn

GSK

Novartis

Boehringer Ingelheim

Teva Pharmaceutical

Abbvie

Kyowa Hakko Kirin Pharma

Astellas Pharma

Desitin Arzneimittel

Endo Pharmaceuticals

F.Hoffmann-La Roche

H.Lundbeck

Valeant

Apokyn

Orion

Stada Arzneimittel

US WorldMeds

Bausch Health

Parkinson Disease Drug Segment by Type

Sinemet-CR

Trastal

Madopar

COMT Inhibitor

Other

Parkinson Disease Drug Segment by Application

Under 40 Years Old

40-65 Years Old

Above 65 Years Old

Parkinson Disease Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Parkinson Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Parkinson Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Parkinson Disease Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Parkinson Disease Drug companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Parkinson Disease Drug Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Parkinson Disease Drug Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Parkinson Disease Drug Market Share by Region (2021-2026) Table 4. Global Parkinson Disease Drug Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Parkinson Disease Drug Market Share by Region (2027-2032) Table 6. Global Parkinson Disease Drug Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Parkinson Disease Drug Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Parkinson Disease Drug Market Size Share by Type (2021-2026) Table 9. Global Parkinson Disease Drug Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Parkinson Disease Drug Market Size Share Forecasted by Type (2027-2032) Table 11. North America Parkinson Disease Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Parkinson Disease Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Parkinson Disease Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Parkinson Disease Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Parkinson Disease Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Parkinson Disease Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Parkinson Disease Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Parkinson Disease Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Parkinson Disease Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Parkinson Disease Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Parkinson Disease Drug Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Parkinson Disease Drug Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Parkinson Disease Drug Market Size Share by Application (2021-2026) Table 24. Global Parkinson Disease Drug Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Parkinson Disease Drug Market Size Share Forecasted by Application (2027-2032) Table 26. North America Parkinson Disease Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Parkinson Disease Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Parkinson Disease Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Parkinson Disease Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Parkinson Disease Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Parkinson Disease Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Parkinson Disease Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Parkinson Disease Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Parkinson Disease Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Parkinson Disease Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Parkinson Disease Drug Industry Trends Table 37. Parkinson Disease Drug Industry Drivers Table 38. Parkinson Disease Drug Industry Opportunities and Challenges Table 39. Parkinson Disease Drug Industry Restraints Table 40. Global Parkinson Disease Drug Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Parkinson Disease Drug Revenue Market Share by Company (2021-2026) Table 42. Global Parkinson Disease Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Parkinson Disease Drug Key Company Headquarters & Area Served Table 44. Global Parkinson Disease Drug Company, Product Type & Application Table 45. Global Parkinson Disease Drug Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Parkinson Disease Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Merck Company Information Table 49. Merck Business Overview Table 50. Merck Parkinson Disease Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Merck Parkinson Disease Drug Product Portfolio Table 52. Merck Recent Development Table 53. Akorn Company Information Table 54. Akorn Business Overview Table 55. Akorn Parkinson Disease Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Akorn Parkinson Disease Drug Product Portfolio Table 57. Akorn Recent Development Table 58. GSK Company Information Table 59. GSK Business Overview Table 60. GSK Parkinson Disease Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. GSK Parkinson Disease Drug Product Portfolio Table 62. GSK Recent Development Table 63. Novartis Company Information Table 64. Novartis Business Overview Table 65. Novartis Parkinson Disease Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Novartis Parkinson Disease Drug Product Portfolio Table 67. Novartis Recent Development Table 68. Boehringer Ingelheim Company Information Table 69. Boehringer Ingelheim Business Overview Table 70. Boehringer Ingelheim Parkinson Disease Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Boehringer Ingelheim Parkinson Disease Drug Product Portfolio Table 72. Boehringer Ingelheim Recent Development Table 73. Teva Pharmaceutical Company Information Table 74. Teva Pharmaceutical Business Overview Table 75. Teva Pharmaceutical Parkinson Disease Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Teva Pharmaceutical Parkinson Disease Drug Product Portfolio Table 77. Teva Pharmaceutical Recent Development Table 78. Abbvie Company Information Table 79. Abbvie Business Overview Table 80. Abbvie Parkinson Disease Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Abbvie Parkinson Disease Drug Product Portfolio Table 82. Abbvie Recent Development Table 83. Kyowa Hakko Kirin Pharma Company Information Table 84. Kyowa Hakko Kirin Pharma Business Overview Table 85. Kyowa Hakko Kirin Pharma Parkinson Disease Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Kyowa Hakko Kirin Pharma Parkinson Disease Drug Product Portfolio Table 87. Kyowa Hakko Kirin Pharma Recent Development Table 88. Astellas Pharma Company Information Table 89. Astellas Pharma Business Overview Table 90. Astellas Pharma Parkinson Disease Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Astellas Pharma Parkinson Disease Drug Product Portfolio Table 92. Astellas Pharma Recent Development Table 93. Desitin Arzneimittel Company Information Table 94. Desitin Arzneimittel Business Overview Table 95. Desitin Arzneimittel Parkinson Disease Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Desitin Arzneimittel Parkinson Disease Drug Product Portfolio Table 97. Desitin Arzneimittel Recent Development Table 98. Endo Pharmaceuticals Company Information Table 99. Endo Pharmaceuticals Business Overview Table 100. Endo Pharmaceuticals Parkinson Disease Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Endo Pharmaceuticals Parkinson Disease Drug Product Portfolio Table 102. Endo Pharmaceuticals Recent Development Table 103. F.Hoffmann-La Roche Company Information Table 104. F.Hoffmann-La Roche Business Overview Table 105. F.Hoffmann-La Roche Parkinson Disease Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. F.Hoffmann-La Roche Parkinson Disease Drug Product Portfolio Table 107. F.Hoffmann-La Roche Recent Development Table 108. H.Lundbeck Company Information Table 109. H.Lundbeck Business Overview Table 110. H.Lundbeck Parkinson Disease Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. H.Lundbeck Parkinson Disease Drug Product Portfolio Table 112. H.Lundbeck Recent Development Table 113. Valeant Company Information Table 114. Valeant Business Overview Table 115. Valeant Parkinson Disease Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Valeant Parkinson Disease Drug Product Portfolio Table 117. Valeant Recent Development Table 118. Apokyn Company Information Table 119. Apokyn Business Overview Table 120. Apokyn Parkinson Disease Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Apokyn Parkinson Disease Drug Product Portfolio Table 122. Apokyn Recent Development Table 123. Orion Company Information Table 124. Orion Business Overview Table 125. Orion Parkinson Disease Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. Orion Parkinson Disease Drug Product Portfolio Table 127. Orion Recent Development Table 128. Stada Arzneimittel Company Information Table 129. Stada Arzneimittel Business Overview Table 130. Stada Arzneimittel Parkinson Disease Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. Stada Arzneimittel Parkinson Disease Drug Product Portfolio Table 132. Stada Arzneimittel Recent Development Table 133. US WorldMeds Company Information Table 134. US WorldMeds Business Overview Table 135. US WorldMeds Parkinson Disease Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 136. US WorldMeds Parkinson Disease Drug Product Portfolio Table 137. US WorldMeds Recent Development Table 138. Bausch Health Company Information Table 139. Bausch Health Business Overview Table 140. Bausch Health Parkinson Disease Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 141. Bausch Health Parkinson Disease Drug Product Portfolio Table 142. Bausch Health Recent Development Table 143. North America Parkinson Disease Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. North America Parkinson Disease Drug Market Size by Country (2021-2026) & (US$ Million) Table 145. North America Parkinson Disease Drug Market Share by Country (2021-2026) Table 146. North America Parkinson Disease Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. North America Parkinson Disease Drug Market Share Forecast by Country (2027-2032) Table 148. Europe Parkinson Disease Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. Europe Parkinson Disease Drug Market Size by Country (2021-2026) & (US$ Million) Table 150. Europe Parkinson Disease Drug Market Share by Country (2021-2026) Table 151. Europe Parkinson Disease Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. Europe Parkinson Disease Drug Market Share Forecast by Country (2027-2032) Table 153. Asia-Pacific Parkinson Disease Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. Asia-Pacific Parkinson Disease Drug Market Size by Country (2021-2026) & (US$ Million) Table 155. Asia-Pacific Parkinson Disease Drug Market Share by Country (2021-2026) Table 156. Asia-Pacific Parkinson Disease Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. Asia-Pacific Parkinson Disease Drug Market Share Forecast by Country (2027-2032) Table 158. Latin America Parkinson Disease Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Latin America Parkinson Disease Drug Market Size by Country (2021-2026) & (US$ Million) Table 160. Latin America Parkinson Disease Drug Market Share by Country (2021-2026) Table 161. Latin America Parkinson Disease Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Latin America Parkinson Disease Drug Market Share Forecast by Country (2027-2032) Table 163. Middle East & Africa Parkinson Disease Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 164. Middle East & Africa Parkinson Disease Drug Market Size by Country (2021-2026) & (US$ Million) Table 165. Middle East & Africa Parkinson Disease Drug Market Share by Country (2021-2026) Table 166. Middle East & Africa Parkinson Disease Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 167. Middle East & Africa Parkinson Disease Drug Market Share Forecast by Country (2027-2032) Table 168. Research Programs/Design for This Report Table 169. Authors List of This Report Table 170. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Parkinson Disease Drug Product Image Figure 3. Global Parkinson Disease Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Parkinson Disease Drug Market Size (2021-2032) & (US$ Million) Figure 5. Global Parkinson Disease Drug Market Share by Region: 2025 VS 2032 Figure 6. Global Parkinson Disease Drug Market Share by Region (2021-2032) Figure 7. North America Parkinson Disease Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Parkinson Disease Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Parkinson Disease Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Parkinson Disease Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Parkinson Disease Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Sinemet-CR Image Figure 13. Global Sinemet-CR Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Trastal Image Figure 15. Global Trastal Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Madopar Image Figure 17. Global Madopar Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. COMT Inhibitor Image Figure 19. Global COMT Inhibitor Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. Other Image Figure 21. Global Other Market Size YoY Growth (2021-2032) & (US$ Million) Figure 22. Global Parkinson Disease Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 23. Global Parkinson Disease Drug Market Share by Type 2025 VS 2032 Figure 24. North America Parkinson Disease Drug Market Size Share by Type (2021-2032) Figure 25. Europe Parkinson Disease Drug Market Size Share by Type (2021-2032) Figure 26. Asia-Pacific Parkinson Disease Drug Market Size Share by Type (2021-2032) Figure 27. Latin America Parkinson Disease Drug Market Size Share by Type (2021-2032) Figure 28. Middle East and Africa Parkinson Disease Drug Market Size Share by Type (2021-2032) Figure 29. Under 40 Years Old Image Figure 30. Global Under 40 Years Old Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. 40-65 Years Old Image Figure 32. Global 40-65 Years Old Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Above 65 Years Old Image Figure 34. Global Above 65 Years Old Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Global Parkinson Disease Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Parkinson Disease Drug Market Share by Application 2025 VS 2032 Figure 37. North America Parkinson Disease Drug Market Size Share by Application (2021-2032) Figure 38. Europe Parkinson Disease Drug Market Size Share by Application (2021-2032) Figure 39. Asia-Pacific Parkinson Disease Drug Market Size Share by Application (2021-2032) Figure 40. Latin America Parkinson Disease Drug Market Size Share by Application (2021-2032) Figure 41. Middle East and Africa Parkinson Disease Drug Market Size Share by Application (2021-2032) Figure 42. Global Top 5 and 10 Parkinson Disease Drug Players Market Share by Revenue in 2025 Figure 43. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 44. North America Parkinson Disease Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 45. North America Parkinson Disease Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 46. North America Parkinson Disease Drug Market Share by Country (2021-2032) Figure 47. Europe Parkinson Disease Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Parkinson Disease Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Parkinson Disease Drug Market Share by Country (2021-2032) Figure 50. Asia-Pacific Parkinson Disease Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 51. Asia-Pacific Parkinson Disease Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 52. Asia-Pacific Parkinson Disease Drug Market Share by Country (2021-2032) Figure 53. Latin America Parkinson Disease Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Latin America Parkinson Disease Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Parkinson Disease Drug Market Share by Country (2021-2032) Figure 56. Middle East & Africa Parkinson Disease Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Middle East & Africa Parkinson Disease Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 58. Middle East & Africa Parkinson Disease Drug Market Share by Country (2021-2032) Figure 59. Years Considered Figure 60. Research Process Figure 61. Key Executives Interviewed

Scope & coverage.

Types
  • Sinemet-CR
  • Trastal
  • Madopar
  • COMT Inhibitor
  • Other
Applications
  • Under 40 Years Old
  • 40-65 Years Old
  • Above 65 Years Old
Companies covered
  • Merck
  • Akorn
  • GSK
  • Novartis
  • Boehringer Ingelheim
  • Teva Pharmaceutical
  • Abbvie
  • Kyowa Hakko Kirin Pharma
  • Astellas Pharma
  • Desitin Arzneimittel
  • Endo Pharmaceuticals
  • F.Hoffmann-La Roche
  • H.Lundbeck
  • Valeant
  • Apokyn
  • Orion
  • Stada Arzneimittel
  • US WorldMeds
  • Bausch Health

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Parkinson Disease Drug Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Parkinson Disease Drug Market Size by Region (2021-2032)
  5. 1.4.1 Global Parkinson Disease Drug Market Size by Region (2021-2026)
  6. 1.4.2 Global Parkinson Disease Drug Market Size by Region (2027-2032)
  7. 1.5 Key Regions Parkinson Disease Drug Market Size (2021-2032)
  8. 1.5.1 North America Parkinson Disease Drug Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Parkinson Disease Drug Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Parkinson Disease Drug Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Parkinson Disease Drug Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Parkinson Disease Drug Market Size Growth Rate (2021-2032)
2 Parkinson Disease Drug Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Sinemet-CR
  3. 2.1.2 Trastal
  4. 2.1.3 Madopar
  5. 2.1.4 COMT Inhibitor
  6. 2.1.5 Other
  7. 2.2 Global Parkinson Disease Drug Market Size by Type
  8. 2.2.1 Global Parkinson Disease Drug Market Size Overview by Type (2021-2032)
  9. 2.2.2 Global Parkinson Disease Drug Historic Market Size Review by Type (2021-2026)
  10. 2.2.3 Global Parkinson Disease Drug Market Size Forecasted by Type (2027-2032)
  11. 2.3 Global Parkinson Disease Drug Market Size by Regions
  12. 2.3.1 North America Parkinson Disease Drug Market Size Breakdown by Type (2021-2026)
  13. 2.3.2 Europe Parkinson Disease Drug Market Size Breakdown by Type (2021-2026)
  14. 2.3.3 Asia-Pacific Parkinson Disease Drug Market Size Breakdown by Type (2021-2026)
  15. 2.3.4 South America Parkinson Disease Drug Market Size Breakdown by Type (2021-2026)
  16. 2.3.5 Middle East and Africa Parkinson Disease Drug Market Size Breakdown by Type (2021-2026)
3 Parkinson Disease Drug Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Under 40 Years Old
  3. 3.1.2 40-65 Years Old
  4. 3.1.3 Above 65 Years Old
  5. 3.2 Global Parkinson Disease Drug Market Size by Application
  6. 3.2.1 Global Parkinson Disease Drug Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global Parkinson Disease Drug Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global Parkinson Disease Drug Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global Parkinson Disease Drug Market Size by Regions
  10. 3.3.1 North America Parkinson Disease Drug Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe Parkinson Disease Drug Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific Parkinson Disease Drug Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America Parkinson Disease Drug Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa Parkinson Disease Drug Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Parkinson Disease Drug Industry Trends
  2. 4.2 Parkinson Disease Drug Industry Drivers
  3. 4.3 Parkinson Disease Drug Industry Opportunities and Challenges
  4. 4.4 Parkinson Disease Drug Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Parkinson Disease Drug Revenue (2021-2026)
  2. 5.2 Global Parkinson Disease Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Parkinson Disease Drug Key Company Headquarters & Area Served
  4. 5.4 Global Parkinson Disease Drug Company, Product Type & Application
  5. 5.5 Global Parkinson Disease Drug Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Parkinson Disease Drug Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Parkinson Disease Drug Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Parkinson Disease Drug Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Merck
  2. 6.1.1 Merck Company Information
  3. 6.1.2 Merck Business Overview
  4. 6.1.3 Merck Parkinson Disease Drug Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Merck Parkinson Disease Drug Product Portfolio
  6. 6.1.5 Merck Recent Developments
  7. 6.2 Akorn
  8. 6.2.1 Akorn Company Information
  9. 6.2.2 Akorn Business Overview
  10. 6.2.3 Akorn Parkinson Disease Drug Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Akorn Parkinson Disease Drug Product Portfolio
  12. 6.2.5 Akorn Recent Developments
  13. 6.3 GSK
  14. 6.3.1 GSK Company Information
  15. 6.3.2 GSK Business Overview
  16. 6.3.3 GSK Parkinson Disease Drug Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 GSK Parkinson Disease Drug Product Portfolio
  18. 6.3.5 GSK Recent Developments
  19. 6.4 Novartis
  20. 6.4.1 Novartis Company Information
  21. 6.4.2 Novartis Business Overview
  22. 6.4.3 Novartis Parkinson Disease Drug Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Novartis Parkinson Disease Drug Product Portfolio
  24. 6.4.5 Novartis Recent Developments
  25. 6.5 Boehringer Ingelheim
  26. 6.5.1 Boehringer Ingelheim Company Information
  27. 6.5.2 Boehringer Ingelheim Business Overview
  28. 6.5.3 Boehringer Ingelheim Parkinson Disease Drug Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Boehringer Ingelheim Parkinson Disease Drug Product Portfolio
  30. 6.5.5 Boehringer Ingelheim Recent Developments
  31. 6.6 Teva Pharmaceutical
  32. 6.6.1 Teva Pharmaceutical Company Information
  33. 6.6.2 Teva Pharmaceutical Business Overview
  34. 6.6.3 Teva Pharmaceutical Parkinson Disease Drug Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Teva Pharmaceutical Parkinson Disease Drug Product Portfolio
  36. 6.6.5 Teva Pharmaceutical Recent Developments
  37. 6.7 Abbvie
  38. 6.7.1 Abbvie Company Information
  39. 6.7.2 Abbvie Business Overview
  40. 6.7.3 Abbvie Parkinson Disease Drug Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Abbvie Parkinson Disease Drug Product Portfolio
  42. 6.7.5 Abbvie Recent Developments
  43. 6.8 Kyowa Hakko Kirin Pharma
  44. 6.8.1 Kyowa Hakko Kirin Pharma Company Information
  45. 6.8.2 Kyowa Hakko Kirin Pharma Business Overview
  46. 6.8.3 Kyowa Hakko Kirin Pharma Parkinson Disease Drug Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Kyowa Hakko Kirin Pharma Parkinson Disease Drug Product Portfolio
  48. 6.8.5 Kyowa Hakko Kirin Pharma Recent Developments
  49. 6.9 Astellas Pharma
  50. 6.9.1 Astellas Pharma Company Information
  51. 6.9.2 Astellas Pharma Business Overview
  52. 6.9.3 Astellas Pharma Parkinson Disease Drug Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Astellas Pharma Parkinson Disease Drug Product Portfolio
  54. 6.9.5 Astellas Pharma Recent Developments
  55. 6.10 Desitin Arzneimittel
  56. 6.10.1 Desitin Arzneimittel Company Information
  57. 6.10.2 Desitin Arzneimittel Business Overview
  58. 6.10.3 Desitin Arzneimittel Parkinson Disease Drug Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Desitin Arzneimittel Parkinson Disease Drug Product Portfolio
  60. 6.10.5 Desitin Arzneimittel Recent Developments
  61. 6.11 Endo Pharmaceuticals
  62. 6.11.1 Endo Pharmaceuticals Company Information
  63. 6.11.2 Endo Pharmaceuticals Business Overview
  64. 6.11.3 Endo Pharmaceuticals Parkinson Disease Drug Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Endo Pharmaceuticals Parkinson Disease Drug Product Portfolio
  66. 6.11.5 Endo Pharmaceuticals Recent Developments
  67. 6.12 F.Hoffmann-La Roche
  68. 6.12.1 F.Hoffmann-La Roche Company Information
  69. 6.12.2 F.Hoffmann-La Roche Business Overview
  70. 6.12.3 F.Hoffmann-La Roche Parkinson Disease Drug Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 F.Hoffmann-La Roche Parkinson Disease Drug Product Portfolio
  72. 6.12.5 F.Hoffmann-La Roche Recent Developments
  73. 6.13 H.Lundbeck
  74. 6.13.1 H.Lundbeck Company Information
  75. 6.13.2 H.Lundbeck Business Overview
  76. 6.13.3 H.Lundbeck Parkinson Disease Drug Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 H.Lundbeck Parkinson Disease Drug Product Portfolio
  78. 6.13.5 H.Lundbeck Recent Developments
  79. 6.14 Valeant
  80. 6.14.1 Valeant Company Information
  81. 6.14.2 Valeant Business Overview
  82. 6.14.3 Valeant Parkinson Disease Drug Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Valeant Parkinson Disease Drug Product Portfolio
  84. 6.14.5 Valeant Recent Developments
  85. 6.15 Apokyn
  86. 6.15.1 Apokyn Company Information
  87. 6.15.2 Apokyn Business Overview
  88. 6.15.3 Apokyn Parkinson Disease Drug Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Apokyn Parkinson Disease Drug Product Portfolio
  90. 6.15.5 Apokyn Recent Developments
  91. 6.16 Orion
  92. 6.16.1 Orion Company Information
  93. 6.16.2 Orion Business Overview
  94. 6.16.3 Orion Parkinson Disease Drug Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 Orion Parkinson Disease Drug Product Portfolio
  96. 6.16.5 Orion Recent Developments
  97. 6.17 Stada Arzneimittel
  98. 6.17.1 Stada Arzneimittel Company Information
  99. 6.17.2 Stada Arzneimittel Business Overview
  100. 6.17.3 Stada Arzneimittel Parkinson Disease Drug Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 Stada Arzneimittel Parkinson Disease Drug Product Portfolio
  102. 6.17.5 Stada Arzneimittel Recent Developments
  103. 6.18 US WorldMeds
  104. 6.18.1 US WorldMeds Company Information
  105. 6.18.2 US WorldMeds Business Overview
  106. 6.18.3 US WorldMeds Parkinson Disease Drug Revenue, Global Share and Gross Margin (2021-2026)
  107. 6.18.4 US WorldMeds Parkinson Disease Drug Product Portfolio
  108. 6.18.5 US WorldMeds Recent Developments
  109. 6.19 Bausch Health
  110. 6.19.1 Bausch Health Company Information
  111. 6.19.2 Bausch Health Business Overview
  112. 6.19.3 Bausch Health Parkinson Disease Drug Revenue, Global Share and Gross Margin (2021-2026)
  113. 6.19.4 Bausch Health Parkinson Disease Drug Product Portfolio
  114. 6.19.5 Bausch Health Recent Developments
7 North America
  1. 7.1 North America Parkinson Disease Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Parkinson Disease Drug Market Size by Country (2021-2026)
  3. 7.3 North America Parkinson Disease Drug Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Parkinson Disease Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Parkinson Disease Drug Market Size by Country (2021-2026)
  3. 8.3 Europe Parkinson Disease Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Parkinson Disease Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Parkinson Disease Drug Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Parkinson Disease Drug Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Parkinson Disease Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Parkinson Disease Drug Market Size by Country (2021-2026)
  3. 10.3 South America Parkinson Disease Drug Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Parkinson Disease Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Parkinson Disease Drug Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Parkinson Disease Drug Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst